Novo Nordisk sues Hims & Hers over copycat weight-loss drugs
Shares in US company fall 16% after FDA announces investigation into unregulated medication
Related reading
Novo Nordisk hits out at rival Hims & Hers over cheaper weight-loss pill
US telehealth group will sell product for $49 a month, a third that of its Danish competitor
Hims & Hers abandons copycat weight-loss drug in face of FDA probe
Novo Nordisk had accused the telehealth company of breaching its patent on Wegovy
Novo Nordisk faces more gloom from price cuts in crowded anti-obesity drugs…
Danish group’s challenges mount despite winning reprieve after Hims & Hers withdraws plan to sell copycat Wegovy pill
Novo Nordisk ends Hims & Hers tie-up over copycat Wegovy drugs
Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments
Hims shares shoot up after weight-loss drug deal with Novo Nordisk
US telehealth group and Danish drugmaker have been in dispute over copycat medicines
Novo Nordisk calls for US import ban on key ingredient for obesity drug copycats
Danish group loses share in diabetes drugs to rivals, with first-half sales growth easing to 8%
